2005
DOI: 10.1080/01676830500187696
|View full text |Cite
|
Sign up to set email alerts
|

Voriconazole in the Treatment of Fungal Osteomyelitis of the Orbit in the Immunocompromised Host

Abstract: Scedosporium apiospermum is an uncommon cause of fungal infection in the orbit and sinus. Morbidity and mortality rates in immunocompromised patients are high. We review the first case of Scedosporium apiospermum orbito-sinus infection that was successfully treated with the new antifungal agent voriconazole. We highlight the efficacy of this drug, particularly in the treatment of osteomyelitis of the orbit and sinus, which may lead to an improvement in survival rates after Scedosporium infection.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
7
0
5

Year Published

2008
2008
2024
2024

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(12 citation statements)
references
References 23 publications
0
7
0
5
Order By: Relevance
“…Voriconazole has been used in children with Scedosporium osteomyelitis [2,7] but as its pharmacokinetics in children appear to be linear, drug level monitoring may be warranted in adjusting voriconazole dosing. In our case voriconazole was administered at a dose of 8 mg/kg/d with favourable response; though the current dose of voriconazole in children is 7 mg/kg twice daily [13].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Voriconazole has been used in children with Scedosporium osteomyelitis [2,7] but as its pharmacokinetics in children appear to be linear, drug level monitoring may be warranted in adjusting voriconazole dosing. In our case voriconazole was administered at a dose of 8 mg/kg/d with favourable response; though the current dose of voriconazole in children is 7 mg/kg twice daily [13].…”
Section: Discussionmentioning
confidence: 99%
“…Empirical antifungal therapy with amphotericin B (1mg/kg/d) was initiated, while antibacterial treatment was discontinued. Following identification of the isolate, as Scedosporium sp., voriconazole IV 8mg/kg/d at a dose recommended for children at that time [1], replaced the amphotericin B regimen, due to the reported good response of Scedosporium infections to voriconazole [2,3]. Marked improvement in clinical symptoms was noted 20 days after voriconazole IV therapy when it was discontinued and she was administered 4 mg/kg every 12 h oral voriconazole, for a total of six months.…”
Section: Case Reportmentioning
confidence: 92%
“…[ 59 60 ] Recently, oral voriconazole, which is also highly active against Aspergillus spp., has gained favor in the management of invasive aspergillosis. [ 61 62 63 ]…”
Section: Fungal Infectionsmentioning
confidence: 99%
“…Treatment recommendations are based on case reports. [165][166][167][168] CNS and eye infections due to S. apiospermum should be treated with voriconazole while combination therapy (voriconazole plus terbinafine) is recommended for CNS/ eye infections due to S. prolificans (grade D recommendation). Posaconazole is an alternative agent but has only been studied as salvage therapy.…”
Section: Cns Disease and Endophthalmitismentioning
confidence: 99%
“…CNS disease and endophthalmitis A solitary mass or multiple brain abscesses are the most frequent CNS manifestations of Scedosporium infections. Treatment recommendations are based on case reports 165–168 …”
mentioning
confidence: 99%